Cisplatin Plus Capecitabine After Adjuvant S-1 in Metastatic Gastric Cancer: A Phase II T-CORE1102 Trial

TAKASHI YOSHIOKA; MASANOBU TAKAHASHI; YASUHIRO SAKAMOTO; AKIRA OKITA; TADAHISA FUKUI; YASUKO MURAKAWA; YOSHIAKI SHINDO; HIROO IMAI; HISATSUGU OHORI; HIDEKAZU SHIROTA; NATSUKO CHIBA; YURIKO (ITO) SASAHARA; TAKASHI NOMURA; NORIMASA FUKUSHIMA; TAKUHIRO YAMAGUCHI; HIDEKI SHIMODAIRA; CHIKASHI ISHIOKA

doi:10.21873/anticanres.15680

Article Information

vol. 42 no. 4 2009-2015

DOI

https://doi.org/10.21873/anticanres.15680

PMID

35347022

Published By

International Institute of Anticancer Research

Print ISSN

0250-7005

Online ISSN

1791-7530

History

Received January 26, 2022
Revision received February 14, 2022
Accepted February 15, 2022
Published online March 28, 2022.

Copyright © 2022 The Author(s). Published by the International Institute of Anticancer Research. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY-NC-ND) 4.0 international license (https://creativecommons.org/licenses/by-nc-nd/4.0).

Author Information

TAKASHI YOSHIOKA¹,^*,
MASANOBU TAKAHASHI²,³,^*,
YASUHIRO SAKAMOTO⁴,
AKIRA OKITA⁴,
TADAHISA FUKUI¹,
YASUKO MURAKAWA⁵,
YOSHIAKI SHINDO⁶,
HIROO IMAI⁷,
HISATSUGU OHORI⁷,
HIDEKAZU SHIROTA¹,²,
NATSUKO CHIBA¹,⁸,
YURIKO (ITO) SASAHARA⁹,
TAKASHI NOMURA¹⁰,
NORIMASA FUKUSHIMA¹⁰,
TAKUHIRO YAMAGUCHI¹¹,
HIDEKI SHIMODAIRA¹,² and
CHIKASHI ISHIOKA²,³,¹² ⇑

¹Department of Clinical Oncology, Yamagata University School of Medicine, Yamagata, Japan;
²Department of Medical Oncology, Tohoku University Hospital, Sendai, Japan;
³Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan;
⁴Department of Medical Oncology, Osaki Citizen Hospital, Osaki, Japan;
⁵Department of Medical Oncology, Miyagi Cancer Center, Medeshima, Japan;
⁶Department of Gastroenterological Surgery, Nakadori General Hospital, Akita, Japan;
⁷Department of Clinical Oncology, Japanese Red Cross Ishinomaki Hospital, Ishinomaki, Japan;
⁸Department of Cancer Biology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan;
⁹Department of Medical Oncology, Yamagata Prefectural Central Hospital, Yamagata, Japan;
¹⁰Department of Surgery, Yamagata Prefectural Central Hospital, Yamagata, Japan;
¹¹Division of Biostatistics, Tohoku University Graduate School of Medicine, Sendai, Japan;
¹²Department of Clinical Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan

Correspondence to: Chikashi Ishioka, Department of Clinical Oncology, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, 980-8575 Japan. Tel: +81 227178543, Fax: +81 227178548, e-mail: chikashi{at}tohoku.ac.jp

View Full Text